The initial success of Viagra undeniably revolutionized the pharmaceutical landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Despite early returns were substantial, the cessation of patents and the appearance of cheaper alternatives have weakened market share. Thus, a thorough assessment